Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dalbavancin for Prolonged IV Therapy in Gram-Positive Infections
NCT03982030Phase 4Withdrawn
- Sponsor
- Wake Forest University Health Sciences
- Start
- Apr 2023
- Primary completion
- Apr 2025
- Modality
- Peptides, Small Molecules
01
Overview
Phase 4, open-label, single-arm trial of dalbavancin in Gram-positive bacterial infection, skin and soft tissue infection (SSTI), infective endocarditis (IE) and 1 more, sponsored by Wake Forest University Health Sciences. Primary endpoint: Number of participants with resolution of infection at Week 6. Planned start Apr 2023; status: withdrawn.
02
Drugs
dalbavancin
03
Conditions
Gram-positive bacterial infectionskin and soft tissue infection (SSTI)infective endocarditis (IE)Bone and osteoarticular infections (BJI)
Beyond the preview
Go deeper on NCT03982030.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03982030.